BRAF and ameloblastoma: In conclusion, BRAF inhibitor therapy represents a significant advancement in the management of ameloblastomas, offering an alternative treatment approach for patients who are not suitable candidates for surgical interventions due to the risk of significant facial deformities and recurrent recurrences.